Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2018045346) MÉTHODES DE TRAITEMENT DU CANCER ET DE DÉTERMINATION DE L'EFFICACITÉ D'UN TRAITEMENT
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

A method for assessing efficacy of Trabedersen therapy in a subject in need thereof, comprising,

determining the levels of cytokines in a sample obtained from the subject,

wherein the subject is undergoing or has undergone treatment comprising administration of therapeutically effective amount of Trabedersen; and

wherein a spike in the level of cytokines relative to reference value indicates that the treatment is efficacious .

A method for prognosing cancer in a subject in need thereof, comprising determining efficacy of treatment by the method of claim 1, wherein determination that the treatment comprising Trabedersen is efficacious is indicative of good prognosis.

The method of claim 1, wherein the subject has undergone at least one cycle of treatment with Trabedersen or is undergoing treatment comprising Trabedersen.

The method of claim 1, wherein the sample is obtained after administration of Trabedersen.

The method of claim 1, wherein the subject has undergone one, two, three, four or more cycles of treatment with Trabedersen.

The method of claim 5, wherein the spike in the cytokine levels after the first and/or second cycle of treatment comprising Trabedersen indicates that the treatment is efficacious.

The method of claim 5, wherein the spike in the cytokine levels after the first and/or second cycle of treatment comprising Trabedersen indicates that the prognosis is good.

The method of claim 5, wherein absence of a spike in the cytokine levels after the first and second cycle of treatment comprising Trabedersen indicates that the treatment is not efficacious.

The method of claim 6, wherein absence of a spike in the cytokine levels after the first and second cycle of treatment comprising Trabedersen is indicative of poor prognosis.

10. The method of claim 1, wherein treatment comprising Trabedersen comprises administering Trabedersen to the subject for at least one cycle to sensitize the tumor to chemotherapeutic agent and subsequently administering the chemotherapeutic agent.

11. The method of claim 11, wherein the chemotherapeutic agents are paclitaxel, dacarbazine, alkylating agents or checkpoint inhibitors.

12. The method of claim 1, wherein the cytokine is IL-8.

13. The method of claim 1, wherein the cytokine is IL-15.

14. The method of claim 1, wherein the cytokine is IL-6.

15. The method of claim 1, wherein the cytokine is IL-8, IL-15, IL6 or a combination thereof.

16. The method of claim 1, wherein the subject has cancer.

17. The method of claim 17, wherein the cancer is pancreatic cancer, melanoma or ovarian cancer.

18. The method of claim 1, wherein the spike in levels of the cytokine is relative to a reference value.

19. The method of claim 11, wherein the reference value is the level of the cytokine in the sample obtained from the same subject prior to treatment with Trabedersen.

20. The method of claim 11, wherein the reference value is the level of the cytokine in a sample obtained from a subject that has cancer and has not been treated with Trabedersen.

21. The method of claim 11, wherein the reference value is the level of the cytokine in a sample obtained from a subject whose cancer is in remission.

22. A method, comprising:

administering a therapeutically effective amount of Trabedersen so a subject diagnosed with cancer, so as to sensitize a tumor in the subject to one or more chemotherapeutic agents;

subsequently administering a therapeutically effective amount of one or more chemotherapeutic agents to the subject; and

determining the levels of cytokines in a sample obtained from the subject, wherein a spike in the level of cytokines indicates that the treatment is efficacious.

23. A method, comprising:

administering a therapeutically effective amount of Trabedersen so a subject diagnosed with cancer, so as to sensitize a tumor in the subject to one or more chemotherapeutic agents; and

determining the levels of cytokines in a sample obtained from the subject, wherein a spike in the level of cytokines indicates that the treatment is efficacious

24. The method of claim 23 or 24, wherein determination that the treatment comprising Trabedersen is efficacious is indicative of good prognosis.

25. The method of claim 23 or 24, wherein the cytokine is IL-8.

26. The method of claim 23 or 24, wherein the cytokine is IL-15.

27. The method of claim 23 or 24, wherein the cytokine is IL-6.

28. The method of claim 23 or 24, wherein the cytokine is IL-8, IL-15, IL6 or a combination thereof.

29. The method of claim 23 or 24, wherein the subject has cancer.

30. The method of claim 30, wherein the cancer is pancreatic cancer, melanoma or ovarian cancer.

31. The method of claim 23 or 24, wherein the sample is obtained after administration of Trabedersen.

32. The method of claim 23 or 24, wherein the spike in levels of the cytokine is relative to a reference value.

33. The method of claim 32, wherein the reference value is the level of the cytokine in the sample obtained from the same subject prior to treatment with Trabedersen.